Darovasertib (LXS196) is a potent, selective and orally active protein kinase C (PKC) inhibitor, with IC50 values of 1.9 nM, 0.4 nM and 3.1 μM for PKCα, PKCθ and GSK3β, respectively. It can be used for the treatment of uveal melanoma.
Loading distributor info...
| Description | Darovasertib (LXS196) is a potent, selective and orally active protein kinase C (PKC) inhibitor, with IC50 values of 1.9 nM, 0.4 nM and 3.1 μM for PKCα, PKCθ and GSK3β, respectively. It can be used for the treatment of uveal melanoma. | ||
|---|---|---|---|
| Targets |
|
| Catalog Num | A19419 |
|---|---|
| Formula | C22H23F3N8O |
| Molecular Weight | 472.47 |
| CAS Number | 1874276-76-2 |
| SMILES | NC1=C(C(NC2=C(N3CCC(C)(N)CC3)C=CC=N2)=O)N=C(C4=NC=CC=C4C(F)(F)F)C=N1 |
| Synonyms | LXS 196, LXS-196 |
| Storage | Store lyophilized at -20ºC, keep desiccated. |
| In vitro | DMSO | 20 mg/mL (42.33 mM) | |
| Water | Insoluble | ||
| Ethanol | 5 mg/mL (10.58 mM) | ||
| * <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. | |||
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.1 mM | 21.17 mL | 105.83 mL | 211.65 mL |
| 0.5 mM | 4.23 mL | 21.17 mL | 42.33 mL |
| 1 mM | 2.12 mL | 10.58 mL | 21.17 mL |
| 5 mM | 0.42 mL | 2.12 mL | 4.23 mL |
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
